US3862302A - Pelletized pregnancy test reagents - Google Patents

Pelletized pregnancy test reagents Download PDF

Info

Publication number
US3862302A
US3862302A US186473A US18647371A US3862302A US 3862302 A US3862302 A US 3862302A US 186473 A US186473 A US 186473A US 18647371 A US18647371 A US 18647371A US 3862302 A US3862302 A US 3862302A
Authority
US
United States
Prior art keywords
reagents
solution
pellets
test
liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US186473A
Inventor
Richard Thompson Price
Stuart Michael Bauer
John Brownlee
Bastiaan Cornelis Goverde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzona Inc
Original Assignee
Akzona Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzona Inc filed Critical Akzona Inc
Application granted granted Critical
Publication of US3862302A publication Critical patent/US3862302A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/76Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/02Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
    • B01J2/06Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a liquid medium
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/02Burettes; Pipettes
    • B01L3/0203Burettes, i.e. for withdrawing and redistributing liquids through different conduits
    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F25REFRIGERATION OR COOLING; COMBINED HEATING AND REFRIGERATION SYSTEMS; HEAT PUMP SYSTEMS; MANUFACTURE OR STORAGE OF ICE; LIQUEFACTION SOLIDIFICATION OF GASES
    • F25CPRODUCING, WORKING OR HANDLING ICE
    • F25C1/00Producing ice
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/963Methods of stopping an enzyme reaction or stabilizing the test materials
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/805Optical property
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/807Apparatus included in process claim, e.g. physical support structures
    • Y10S436/81Tube, bottle, or dipstick
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/811Test for named disease, body condition or organ function
    • Y10S436/814Pregnancy
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/815Test for named compound or class of compounds
    • Y10S436/817Steroids or hormones
    • Y10S436/818Human chorionic gonadotropin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/826Additives, e.g. buffers, diluents, preservatives

Definitions

  • ABSTRACT Pelletized analytical and immunological reagents are prepared in a stable accurate form containing predetermined and pretested measured amounts of sub-' stances capable of participating in analytical and immunological reactions, such as pregnancy tests, by forming these reagents into frozen and freeze-dried beads or spheres; a set of these pellets comprising an antiserum and an antigen is placed in a test vessel and moistened with the liquid to be tested and then allowed to stand until agglutination or precipitin reaction does or does not occur.
  • the present invention relates to novel pelletized reagents, test methods, and apparatus for performing invitro analytical and immunological reactions, and particularly diagnostic tests therewith.
  • the analytical and immunological tests with which the present invention 'is concerned are most commonly laboratory tests which have as their objective the determination of the presence or absence of antigens or antibodies or enzymes in body fluids as an aid in the diagnosis of certain physiological or pathological conditions in humans and animals-
  • the reaction may result in the formation of a precipitate in which case it is known as a precipitin reaction.
  • the reaction is between substances distributed in a liquid medium, at least one of which substances is a solid which becomes agglomerated, the reaction is known as an agglutination reaction.
  • the formation of the precipitate, or the agglutination or inhibition of agglutination of specially-treated particles is manifested visually in the way the precipitate forms or the particles arrange themselvesfollowing reaction.
  • the immunologicaltests which may include, for example, tests for blood group type, pregnancy, and similar phenomena, are customarily performed with reagents such as, for example, a suspension of sensitized erythrocytes, and a solution of suitable antiserum, dispensed into a test vial from a dropper.
  • reagents such as, for example, a suspension of sensitized erythrocytes, and a solution of suitable antiserum
  • a principal object of the present invention is to provide in a single container, all the necessary analytical reagents for diagnostic tests of the types previously described in a pelletized form in which they are stable, ac-
  • Another object of the invention is to provide a method for the manufacture of pelletized analytical, immunological, or diagnostic reagents which is inexpensive and practical and which doesv not require special elaborate equipment but which may be carried out conveniently for commercial purposes on a large scale. Still another object is to make the reagents for diagnostic tests available in a convenient form while at the same time insuring the accuracy of the amounts of reagents present to provide dependable test resultsQStill another object is to provide a method that permits two or more otherwise incompatible substances to be freeze-dried in a single container, while avoiding premature reaction which might come about in the presence of moisture. A further objective is to provide a person performing a diagnostic test with a simple container device in which the reagents are present in pelletized form so that the test results can be visually observed.
  • novel dry solid stable pelletized analytical, diagnostic, and immunological reagents in the form of beads or small spheres, each furnishing a predetermined and accurately measured quantity of the reagent.
  • the reagents from which the pellets are prepared are reactive and may even be mutually incompatible, the pellets themselves have the advantage that they are stable and may be present together in a common container for an indefinite period of time without interaction.
  • the reagents in the pellets are readily reconstituted and made ready for an analytical, immunological or diagnostic test by the simple addition thereto of the liquid to be tested.
  • composition, preparation and use of the pelletized reagents of the invention will be specifically illustr'ated with respect to reagents for an immunological or diagnostic test for detecting the presence of human chorionic gonadotropic (HCG) in urine, which test is utilized in the diagnosis of pregnancy.
  • HCG human chorionic gonadotropic
  • auxiliary substances such as buffers, may also be pelletized in accordance with the invention and may be utilized in dry stable form in conjunction with one or more diagnostic test reagent pellets.
  • the process of preparation of the pelletized reagents of the invention broadly comprises the steps of:
  • the pellets may then be dried by any suitable method, but freeze-drying is preferred.
  • FIG. 1 depicts in diagrammatic form a system for the formation of drops of reagent and the freezing thereof to solid stable pellets.
  • an aqueous solution or suspension containing a known concentration of the reagent is first prepared.
  • a suitable quantity of an inert matrix-producing substance or bulking agent which aids in giving body to the freezedried pellet.
  • suitable bulking agents include sugars, such as sucrose, mannose, lactose and mannitol, proteinaceous materials, such as serum protein, lactalbumin hydrolysate, and casein hydrolysate.
  • the reagent solution or suspension is pumped from its storage vessel 1 through a flexible conduit 2, which may be made of plastic, for example, transparent polyethylene tubing, by means of a proportioning pump 3.
  • a proportioning pump 3 This is preferably a pulsating type pump which compresses the flexible tubing by means of rollers, thereby measuring a predetermined amount of solution per unit time.
  • a pump which delivers about 2.0 ml per minute is used.
  • the solution flows through a pulse suppressor 4 so that a nearly uniform flow is maintained.
  • the solution passes to a special type of dropping pipet 5 which discharges a predetermined, accurately measured amount in the form of a drop.
  • Such a drop may contain, for example. from about 0.025 to about 0.07 ml.
  • For HCG antiserum and antigen solutions precisely 0.05 ml is chosen. since this provides frozen pellets of suitable size for testing purposes.
  • the pipette 5 is positioned at a suitable height above the surface of a body of water-immiscible liquid 6 which is held in a container 7, and in which the drop is frozen.
  • the pipet is at such a height above the level of the water-immiscible liquid that splashing is prevented while at the same time the height allows for a free fall of the drop which results in proper drop size and formation of true spherical shape, either before or after entry into the water-immiscible liquid.
  • a suction tube 8 is placed at an appropriate level. As the hexane is displaced by the aqueous volume introduced as drops this suction line pulls off excess hexane and thereby maintains a constant level.
  • the water-immiscible liquid used for freezing may be a liquid hydrocarbon or a liquid halogenated hydrocarbon, or mixtures thereof.
  • suitable liquids include hexane, carbon disulfide, chloroform, heptane, iso-octane, or toluene, as well as mixtures such as hexane-chloroform or benzene-hexane. These mixtures are designed so that they will always have a density less than water. For example, hexane has a specific gravity of 0.6593 at /4C.
  • the specific gravity can be ad- 5 justed to any desired level by blending with the hexane another liquid such as carbon tetrachloride, in order to maintain a controlled rate of fall of the drop.
  • the rate of fall is advantageously of the order of about 1 foot per 2 seconds, depending upon the length of the liquid column. The longer the column, the faster the rate of fall which can be maintained.
  • the body of freezing liquid is maintained with a temperature gradient which ranges from near ambient at its upper surface and diminishes in the direction of the bottom of the liquid in such a manner that the temperature drops to about C. in the bottom portion.
  • the liquid is maintained for a short distance below its upper surface at a temperature between about 0 and 20C. Below this level the cooling of the liquid is arranged in such a manner that the temperature drops to 70C. in the bottom portion.
  • cryogenic liquids such as liquid nitrogen which has a boiling point of -143C., or liquid oxygen which has a boiling point of 183C., may also be employed.
  • the desired temperature of the liquid column is achieved either by use of a freezing mixture which sur rounds the body of liquid or by mechanical refrigeration to equivalent temperatures.
  • the freezing mixture may be a combination of dry ice and acetone, or of dry ice and methyl Cellosolve (diethylene glycol monomethyl ether).
  • the upper level of the refrigerated portion of the liquid which is maintained between about 0C. and 20C., comprises a zone extending not more than about 6 inches below the surface of the liquid. This provides a 6 inch fall at a temperature above freezing and thus an opportunity for formation of a truly spherical pellet.
  • the frozen beads collect on the bottom and can be removed and freeze-dried to produce stable dry spheres containing accurately measured quantities of desired reagents.
  • the frozen spheres are preferably collected in a wire mesh basket and may be readily handled mechanically so that they may be placed into any pre chilled container, such as a test tube, and freeze-dried in situ.
  • the frozen spheres are stored under refrigeration at temperatures of 50C. or lower to prevent crystal growth within the spheres, which might cause them to become friable.
  • one or more spheres of selected reagents are placed in a prechilled container and transferred without warming to the prechilled shelves of a conventional freeze-drying apparatus in which the drying takes place, for example, at a starting temperature of 50C. and rising during the drying to +37C. at the finish and at a pressure not higher than about p. at the start and approaching Su at the finish which is 18 hours to 24 hours later.
  • test tube may then be capped utilizing a moisture-proof closure and stored for an indefinite period.
  • a testing device of this kind' is shown in FIG. 2 of the drawings.
  • the test device comprises a tubular container having a transparent sidewall and bottom portion adapted to receive the liquid to be tested and provided with a moisture-proof closure.
  • a reagent pellet prepared in accordance with the invention.
  • the liquid tobe tested is applied to the pellet or pellets by opening the closure and introducing a measured amount of the liquid by means of a dropper.
  • the test pellets can be used for performing any immunological test in which two incompatible test reagents are present in the same tube, such as, for example, the pregnancy test described more fully below, and also test for blood group substances in plasma and serum, blood group typing, and antigens and antibodies of various kinds, including rheumatoid factor. syphilis antigen, antistreptolysin O, infectious mononucleosis, and other agglutination or precipitin tests.
  • a pellet of the substance being tested for can be treated in a separate test alongside the actual specimen to be tested, using two tubes, e.g., a freezedried pellet of known pregnant urine.
  • EXAMPLE 2 Preparationof Pellets of Sensitized Erythrocytes
  • a suspension of sheep erythrocytes is treated in conventional manner with formalin and tannin and centrifuged and washedwith a phosphate sodium chloride buffer of pH 6.4 and then incorporated in this buffer.
  • a phosphate sodium chloride buffer of pH 6.4 To this mixture there is added an equal volume of a solution of 501.U. HCG per ml. in a buffer of pH 6.4.
  • the mixture is stored for 48 hours at 37C., whereupon formaldehyde is added until final concentration is obtained of 0.25% (wt/vol) formaldehyde.
  • Erythrocyte pellets are produced by reconstituting the previously freeze-dried, sensitized erythrocytes to five-sixths of the original volume, i.e., 12 ml of freezedried 6.67% suspension in final suspension medium are reconstituted with 10 ml of distilled water. This suspension is pumped to a microtiter dropping pipet. Fine bore polyethylene tubing (ID. 0.023 inch) is used to minimize erythrocytes settling and the pump is not turned off during the process except momentarily.
  • the suspension is converted into calibrated drops aspreviously described which are allowed to fall through a column of hexane cooled by a mixture of dry icemethyl Cellosolve, the temperature of the hexane ranging from about ambient at its upper surface to -C. near the bottom of the column.
  • the pellets are col- Ec te d and stored as in Example 1.
  • the above salts are dissolved in about 150 ml of water.
  • the solution is adjusted to pH 7.2 with 5.0 N NaOH, then q.s. with water to 170 ml.
  • 0.2 ml of a stock dye solution consisting of a 1.0 mg/ml solution store dye solution in the refrigerator. This solution need not be refrigerated during the production of the pellets.
  • the buffer pellets are produced in an identical manner to that described for the antiserum pellets. Subsequent to production, the handling and storage are the same.
  • EXAMPLE 4 Method of Performing Pregnancy Test
  • One of each of the antiserum, HCG sensitized erythrocytes, and buffer pellets are placed in the bottom of the test vial shown in FIG. 2 of the drawings.
  • the test vial is then recapped and shaken up and down for 30 seconds. after which it is allowed to stand undisturbed for a period of 2 hours.
  • the bottom of the vial is visually inspected for a positive or negative indication of agglutination.
  • the formation of a donut-shaped ring is a positive indication of pregnancy.
  • Solution 1 250 ml 3 millimolar aqueous solution of reduced nicotinamide-adenine-dinucleotide. The fresh solution is kept at 0 4C. until needed.
  • Solution 2 500 ml aqueous solution of lactic acid dehydrogenase, having at least 180,000 I.U. LDH-activity per litre. The fresh solution is kept at 0 4C. until needed.
  • Solution 3 1250 ml 0.2 molar aqueous solution of L- alanine.
  • Solution solutions 4 3000 ml of an aqueous solution which is 5 millimolar in ethylenediamine .tetraacetic acid and 50- millimolar in triethanolamine. The pH of this solution has been adjusted to a pH of 7.5.
  • Buffer-enzyme pellets are prepared from the foregoing mixture as described in Example I. They are filled into small polyethylene vials as shown in FIG. 2, each vial containing that number of pellets corresponding with 0.5 ml of the buffered solution.
  • Solution 5 200 ml 0.2 molar aqueous sodium-a-keto glutarate. The fresh solution is kept at 0 4C. until needed.
  • Solution 6 800 ml of an aqueous solution having the composition of solution 4.
  • Solution 6 is cooled to 0 4C. and then thoroughly mixed with solution 5.
  • Buffer-substrate pellets of 0.1 ml of this mixed solution are prepared according to Example I. They are filled into small polyethylene vials as shown in FIG. 2, each vial containing one pellet. After lyophilization the vials are closed with blue screw caps.
  • a pregnancy test reagent adapted for detecting the presence of human chorionic gonadotropin in urine consisting essentially of astable frozen and freeze-dried pellet containing a predetermined immunologically effective amount for test purposes of human chorionic gonadotropin antiserum together, with an effective amount of a phosphate buffer.

Abstract

Pelletized analytical and immunological reagents are prepared in a stable accurate form containing predetermined and pretested measured amounts of substances capable of participating in analytical and immunological reactions, such as pregnancy tests, by forming these reagents into frozen and freeze-dried beads or spheres; a set of these pellets comprising an antiserum and an antigen is placed in a test vessel and moistened with the liquid to be tested and then allowed to stand until agglutination or precipitin reaction does or does not occur.

Description

atent 1 Price et al.
1 1 PELLETIZED PREGNANCY TEST REAGENTS [75] Inventors: Richard Thompson Price, Verona; Stuart Michael Bauer, Parsippany, both of N.J.; John Brownlee, West Seneca, N.Y.; Bastiaan Cornelis Goverde, Oss, Netherlands [73] Assignee: Akzona Incorporated, Asheville,
[22] Filed: Oct. 4, 1971 [21] Appl. No.: 186,473
Related US. Application Data [62] Division of Ser. No. 808,803, March 20, 1969, Pat.
[52] US Cl 424/12, 34/92; 424/3, 424/11, 424/13, 424/101 [51] Int. Cl...... F26b 5/06, GOln 1/00, GOln 33/16 [58] Field of Search ..424/3,11,12,13,101; 264/13, 14; 34/92; 62/66 [56] References Cited UNITED STATES PATENTS 3,236,732 2/1966 Arquilla 424/12 3,344,617 10/1967 Rinfret 264/14 3,548.051 12/1970 Dingwall 424/12 1 Jan. 21, 1975 5/1971 Crane 424/12 4/1972 Schuurs ..424/12 OTHER PUBLICATIONS Primary ExaminerAlbert T. Meyers Assistant Examiner-A. P. Fagelson Attorney, Agent, or FirmHugo E. Weisberger [57] ABSTRACT Pelletized analytical and immunological reagents are prepared in a stable accurate form containing predetermined and pretested measured amounts of sub-' stances capable of participating in analytical and immunological reactions, such as pregnancy tests, by forming these reagents into frozen and freeze-dried beads or spheres; a set of these pellets comprising an antiserum and an antigen is placed in a test vessel and moistened with the liquid to be tested and then allowed to stand until agglutination or precipitin reaction does or does not occur.
2 Claims, 2 Drawing Figures PELLETIZED PREGNANCY TEST REAGENTS CROSS-REFERENCE TO RELATED APPLICATION This application is a division of application Ser. No. 808,803, filed 3/20/69, now US. Pat. No. 3,655,838, issued Apr. ll, 1972.
BACKGROUND OF THE INVENTION The present invention relates to novel pelletized reagents, test methods, and apparatus for performing invitro analytical and immunological reactions, and particularly diagnostic tests therewith.
The analytical and immunological tests with which the present invention 'is concerned are most commonly laboratory tests which have as their objective the determination of the presence or absence of antigens or antibodies or enzymes in body fluids as an aid in the diagnosis of certain physiological or pathological conditions in humans and animals-Depending upon the particular combination of reagents and test liquid employed, the reaction may result in the formation of a precipitate in which case it is known as a precipitin reaction. Where the reaction is between substances distributed in a liquid medium, at least one of which substances is a solid which becomes agglomerated, the reaction is known as an agglutination reaction. The formation of the precipitate, or the agglutination or inhibition of agglutination of specially-treated particles is manifested visually in the way the precipitate forms or the particles arrange themselvesfollowing reaction.
The immunologicaltests, which may include, for example, tests for blood group type, pregnancy, and similar phenomena, are customarily performed with reagents such as, for example, a suspension of sensitized erythrocytes, and a solution of suitable antiserum, dispensed into a test vial from a dropper. Even though the suspension of erythrocytes may have been titered very carefully the use of vials and droppers is not only expensive, but is likely to result in questionable findings because of the limitations in the accuracy of ordinary droppers. Such droppers are usually uncalibrated, and although the accuracy of the drop'size is of great importance, such accuracy is rarely attained and the size of the drops is variable and undependable.
In view of the shortcomings of the vial-dropper test methods, it has been proposed in the prior art to carry out agglutination reactions by depositing an accurately measured drop of a reagent onto a slide or cardboard supporting surface and allowing the drop to be dried, whereupon the test liquid can subsequently be deposited thereon to observe the results. Methods of this type are also subject to inaccuracies in the application of the reagents as well as the observations made.
It is also frequently necessary for immunological reagents, such as sensitized erythrocytes, or sensitive protein materials, to be preserved by refrigeration. This necessarily involves the presence of special refrigeration equipment and is space-consuming and 'also timeconsuming because of the problem of transferring refrigerated solutions. Efforts have been made to overcome the limitations of the vial-dropper test methods, and the slide type methods, by subjecting reagents, which may be incompatible with each other in the presence of moisture, to freezing in successive layers in a container and thereafter freeze-drying the frozen strata, and a method of this type is described in US.
Pat. No. 3,269,905 However, such a procedure requires special apparatus and technical knowledge and is expensive and time-consuming to carry out.
GENERAL DESCRIPTION OF THE INVENTION A principal object of the present invention is to provide in a single container, all the necessary analytical reagents for diagnostic tests of the types previously described in a pelletized form in which they are stable, ac-
curate in unit content, and completely non-reactive until they are contacted by the liquid to be tested. Another object of the invention is to provide a method for the manufacture of pelletized analytical, immunological, or diagnostic reagents which is inexpensive and practical and which doesv not require special elaborate equipment but which may be carried out conveniently for commercial purposes on a large scale. Still another object is to make the reagents for diagnostic tests available in a convenient form while at the same time insuring the accuracy of the amounts of reagents present to provide dependable test resultsQStill another object is to provide a method that permits two or more otherwise incompatible substances to be freeze-dried in a single container, while avoiding premature reaction which might come about in the presence of moisture. A further objective is to provide a person performing a diagnostic test with a simple container device in which the reagents are present in pelletized form so that the test results can be visually observed.
PELLETIZ-ED REAGENTS In accordance with a first aspect of the present invention, there are provided novel dry solid stable pelletized analytical, diagnostic, and immunological reagents in the form of beads or small spheres, each furnishing a predetermined and accurately measured quantity of the reagent. Even though the reagents from which the pellets are prepared are reactive and may even be mutually incompatible, the pellets themselves have the advantage that they are stable and may be present together in a common container for an indefinite period of time without interaction. However, the reagents in the pellets are readily reconstituted and made ready for an analytical, immunological or diagnostic test by the simple addition thereto of the liquid to be tested.
The composition, preparation and use of the pelletized reagents of the invention will be specifically illustr'ated with respect to reagents for an immunological or diagnostic test for detecting the presence of human chorionic gonadotropic (HCG) in urine, which test is utilized in the diagnosis of pregnancy.
However, it will be readily understood by those skilled in this art that the principles of the invention are not to be regarded as limited thereto, but may be extended to the preparation and use of a wide range of pelletized analytical, immunological, and diagnostic reagents, and to a wide variety of tests which may employ one or a multiplicity of different pelletized reagents. Furthermore, auxiliary substances, such as buffers, may also be pelletized in accordance with the invention and may be utilized in dry stable form in conjunction with one or more diagnostic test reagent pellets.
The process of preparation of the pelletized reagents of the invention broadly comprises the steps of:
a. forming an aqueous solution or suspension of the reagent having a predetermined concentration;
b. forming an accurately measured or calibrated,
free-falling drop of said solution or suspension;
c. allowing said drop to fall through a body of a water-immiscible liquid having a density less than that of water and having a temperature gradient ranging from approximately ambient at its upper surface to at most a temperature below the freezing point of the solution being frozen at the lower portion of the column, thereby freezing said drops to frozen pellets or beads; and
d. collecting the frozen pellets containing a predetermined quantity of the reagent at the bottom of said body of liquid. The pellets may then be dried by any suitable method, but freeze-drying is preferred.
The method of preparation of the pellets of the invention will be better understood by reference to the accompanying drawings, in which FIG. 1 depicts in diagrammatic form a system for the formation of drops of reagent and the freezing thereof to solid stable pellets.
Referring to FIG. 1, an aqueous solution or suspension containing a known concentration of the reagent is first prepared. Advantageously there is'incorporated into the solution or suspension a suitable quantity of an inert matrix-producing substance or bulking agent, which aids in giving body to the freezedried pellet. Examples of suitable bulking agents include sugars, such as sucrose, mannose, lactose and mannitol, proteinaceous materials, such as serum protein, lactalbumin hydrolysate, and casein hydrolysate.
The reagent solution or suspension is pumped from its storage vessel 1 through a flexible conduit 2, which may be made of plastic, for example, transparent polyethylene tubing, by means of a proportioning pump 3. This is preferably a pulsating type pump which compresses the flexible tubing by means of rollers, thereby measuring a predetermined amount of solution per unit time. To form accurate drops, a pump which delivers about 2.0 ml per minute is used. From the pump 3 the solution flows through a pulse suppressor 4 so that a nearly uniform flow is maintained. Thence the solution passes to a special type of dropping pipet 5 which discharges a predetermined, accurately measured amount in the form of a drop. Such a drop may contain, for example. from about 0.025 to about 0.07 ml. For HCG antiserum and antigen solutions precisely 0.05 ml is chosen. since this provides frozen pellets of suitable size for testing purposes.
The pipette 5 is positioned at a suitable height above the surface of a body of water-immiscible liquid 6 which is held in a container 7, and in which the drop is frozen. The pipet is at such a height above the level of the water-immiscible liquid that splashing is prevented while at the same time the height allows for a free fall of the drop which results in proper drop size and formation of true spherical shape, either before or after entry into the water-immiscible liquid. In order to maintain the height from which the drop falls to prevent drop distortion and splash, a suction tube 8 is placed at an appropriate level. As the hexane is displaced by the aqueous volume introduced as drops this suction line pulls off excess hexane and thereby maintains a constant level.
The water-immiscible liquid used for freezing may be a liquid hydrocarbon or a liquid halogenated hydrocarbon, or mixtures thereof. Examples of suitable liquids include hexane, carbon disulfide, chloroform, heptane, iso-octane, or toluene, as well as mixtures such as hexane-chloroform or benzene-hexane. These mixtures are designed so that they will always have a density less than water. For example, hexane has a specific gravity of 0.6593 at /4C. The specific gravity can be ad- 5 justed to any desired level by blending with the hexane another liquid such as carbon tetrachloride, in order to maintain a controlled rate of fall of the drop. The rate of fall is advantageously of the order of about 1 foot per 2 seconds, depending upon the length of the liquid column. The longer the column, the faster the rate of fall which can be maintained.
The body of freezing liquid is maintained with a temperature gradient which ranges from near ambient at its upper surface and diminishes in the direction of the bottom of the liquid in such a manner that the temperature drops to about C. in the bottom portion. Advantageously the liquid is maintained for a short distance below its upper surface at a temperature between about 0 and 20C. Below this level the cooling of the liquid is arranged in such a manner that the temperature drops to 70C. in the bottom portion. However, any lower temperature than this figure can also be utilized, depending upon the nature of the liquid and the reagent being treated. For example, cryogenic liquids such as liquid nitrogen which has a boiling point of -143C., or liquid oxygen which has a boiling point of 183C., may also be employed.
The desired temperature of the liquid column is achieved either by use of a freezing mixture which sur rounds the body of liquid or by mechanical refrigeration to equivalent temperatures. For example, the freezing mixture may be a combination of dry ice and acetone, or of dry ice and methyl Cellosolve (diethylene glycol monomethyl ether).
Advantageously the upper level of the refrigerated portion of the liquid, which is maintained between about 0C. and 20C., comprises a zone extending not more than about 6 inches below the surface of the liquid. This provides a 6 inch fall at a temperature above freezing and thus an opportunity for formation of a truly spherical pellet.
In this way spherical drops are formed which freeze into beads as they descend through the liquid column. The frozen beads collect on the bottom and can be removed and freeze-dried to produce stable dry spheres containing accurately measured quantities of desired reagents. The frozen spheres are preferably collected in a wire mesh basket and may be readily handled mechanically so that they may be placed into any pre chilled container, such as a test tube, and freeze-dried in situ. Advantageously the frozen spheres are stored under refrigeration at temperatures of 50C. or lower to prevent crystal growth within the spheres, which might cause them to become friable.
For purposes of freeze-drying, one or more spheres of selected reagents are placed in a prechilled container and transferred without warming to the prechilled shelves of a conventional freeze-drying apparatus in which the drying takes place, for example, at a starting temperature of 50C. and rising during the drying to +37C. at the finish and at a pressure not higher than about p. at the start and approaching Su at the finish which is 18 hours to 24 hours later.
Where the reagent pellets are placed into a suitable test tube for future use the test tube may then be capped utilizing a moisture-proof closure and stored for an indefinite period. A testing device of this kind'is shown in FIG. 2 of the drawings.
' As will be apparent from the drawings, the test device comprises a tubular container having a transparent sidewall and bottom portion adapted to receive the liquid to be tested and provided with a moisture-proof closure. There is placed in the container at least one reagent pellet prepared in accordance with the invention. The liquid tobe tested is applied to the pellet or pellets by opening the closure and introducing a measured amount of the liquid by means of a dropper.
It is apparent that the principles of the invention can be applied not only to the preparation of analytical reagents but also to the preparation of pharmaceutical dosage forms, particularly those involving'small dosages of the medicament involved.
In the field of immunology by the selection of appropriate reagents, the test pellets can be used for performing any immunological test in which two incompatible test reagents are present in the same tube, such as, for example, the pregnancy test described more fully below, and also test for blood group substances in plasma and serum, blood group typing, and antigens and antibodies of various kinds, including rheumatoid factor. syphilis antigen, antistreptolysin O, infectious mononucleosis, and other agglutination or precipitin tests. Moreover, in order to demonstrate to a'user of the test device what a proposed reaction looks like, or as a control, a pellet of the substance being tested for can be treated in a separate test alongside the actual specimen to be tested, using two tubes, e.g., a freezedried pellet of known pregnant urine.
DESCRIPTION OF THE PREFERRED EMBODIMENTS The following examples are indicative of a presently preferred embodiment of the invention but are not to be considered as limiting the invention thereto.
The preparation of a set of test reagent pellets for the detection of human chorionic gonadotropin in urine is disclosed in the following examples:
EXAMPLE 1 Preparation of l-ICG Antiserum Pellets The reagents are Sucrose 10.2 Gm.
Sodium Chloride 0.765 Gm.
Dihusic Sodium Phosphate Heptahydrate 2.462 Gm.
(Na HPO 7H O) Monohasic Potassium Phosphate 0.489 Gm.
(KH- ,PO
Distilled water. q.s. 17(5) .0 ml.
Anti-human chorionic gonadotropin q.s. to yield sensitivity factor of 650 800 LU. HCG/liter and 5. 5. 3-l. 2-0 reactions with urine at 0. $00. 750. and 1000 I.U./liter urine, respectively. A reaction graded 5 is complete agglutination and is complete inhibition.
EXAMPLE 2 Preparationof Pellets of Sensitized Erythrocytes A suspension of sheep erythrocytes is treated in conventional manner with formalin and tannin and centrifuged and washedwith a phosphate sodium chloride buffer of pH 6.4 and then incorporated in this buffer. To this mixture there is added an equal volume of a solution of 501.U. HCG per ml. in a buffer of pH 6.4. The mixture is stored for 48 hours at 37C., whereupon formaldehyde is added until final concentration is obtained of 0.25% (wt/vol) formaldehyde. Next this mixture is stored for 15 hours at 37C., whereupon the erythrocytes are again centrifuged, washed with physiological salt solution, incorporated as 10% v/v suspension in a physiological salt solution containing 0.1% of bovine serumalbumin and stored until needed at 0- 4C. Thereafter the erythrocytes are centrifuged,
washed with physiological salt solution and freezedried in conventional-manner. Alternatively the formolized tanned cells are washed and suspended in a phosphate sodium chloride buffer at pH 7.6. To this mixture is added an equal volume of a solution of 50 I.U. I-ICG/ml. This mixture is maintained at 56C. for 18 hours, then washed and resuspended in 0.9% sodium chloride and mixed equal parts with a solution of formaldehyde (1.5%) in 0.9% saline. This mixture is stored at 2 -8C. for about 1 week whereupon the erythrocytes are again washed with 0.9% sodium chloride and finally suspended to a concentration of 6.6% in a mixture of pH 712 phosphate buffer containing sucrose 6% and bovine serumalbumin 1.5%. This mixture is freeze-dried and held dry until needed. The sheep erythrocytes which have thus been sensitized by chemically affixing HCG to their surfaces are suspended in a mixture of bufferand a diluent such as sucrose and bovine serumalbumin, so that there is contained in each 0.05 ml the precise optimal quantity for a single HCG test.
Erythrocyte pellets are produced by reconstituting the previously freeze-dried, sensitized erythrocytes to five-sixths of the original volume, i.e., 12 ml of freezedried 6.67% suspension in final suspension medium are reconstituted with 10 ml of distilled water. This suspension is pumped to a microtiter dropping pipet. Fine bore polyethylene tubing (ID. 0.023 inch) is used to minimize erythrocytes settling and the pump is not turned off during the process except momentarily.
The suspension is converted into calibrated drops aspreviously described which are allowed to fall through a column of hexane cooled by a mixture of dry icemethyl Cellosolve, the temperature of the hexane ranging from about ambient at its upper surface to -C. near the bottom of the column. The pellets are col- Ec te d and stored as in Example 1. I
EXAMPLE 3 Preparation of Buffer Pellets The reagents are:
The above salts are dissolved in about 150 ml of water. The solution is adjusted to pH 7.2 with 5.0 N NaOH, then q.s. with water to 170 ml. Then add 0.2 ml of a stock dye solution consisting of a 1.0 mg/ml solution (store dye solution in the refrigerator). This solution need not be refrigerated during the production of the pellets.
The buffer pellets are produced in an identical manner to that described for the antiserum pellets. Subsequent to production, the handling and storage are the same.
EXAMPLE 4 Method of Performing Pregnancy Test One of each of the antiserum, HCG sensitized erythrocytes, and buffer pellets are placed in the bottom of the test vial shown in FIG. 2 of the drawings. There is introduced into the test vial by means of a dropper a sample of the urine to be tested and thereafter an additional volume of water is introduced equal to about four times the amount of urine added. The test vial is then recapped and shaken up and down for 30 seconds. after which it is allowed to stand undisturbed for a period of 2 hours. The bottom of the vial is visually inspected for a positive or negative indication of agglutination. The formation of a donut-shaped ring is a positive indication of pregnancy.
Pyruvic acid NADH '2, L-lactic acid NAD In the foregoing equations, the abbreviations mean:
G.P.T. glutamate-pyruvate transaminase NADH nicotinamide-adenine-dinucleotide, re-
duced form NAD nicotinamide-adenine-dinucleotide, oxidized form LDH lactic acid dehydrogenase For each molecule pyruvic acid originating from reaction (I), one molecule of NADH is oxidized to NAD. The decrease in optical density is determined directly in U. V. at 334 nm in a 25C. photometer cuvette.
a. Preparation of buffer-enzyme pellets The following reagents solutions are prepared:
Solution 1: 250 ml 3 millimolar aqueous solution of reduced nicotinamide-adenine-dinucleotide. The fresh solution is kept at 0 4C. until needed.
Solution 2: 500 ml aqueous solution of lactic acid dehydrogenase, having at least 180,000 I.U. LDH-activity per litre. The fresh solution is kept at 0 4C. until needed. I
Solution 3: 1250 ml 0.2 molar aqueous solution of L- alanine.
Solution solutions 4: 3000 ml of an aqueous solution which is 5 millimolar in ethylenediamine .tetraacetic acid and 50- millimolar in triethanolamine. The pH of this solution has been adjusted to a pH of 7.5.
The soutions 3 and 4 are thoroughly mixed and cooled to 0 4C. Then the solutions I and 2 are added and the solution is thoroughly stirred.
Buffer-enzyme pellets are prepared from the foregoing mixture as described in Example I. They are filled into small polyethylene vials as shown in FIG. 2, each vial containing that number of pellets corresponding with 0.5 ml of the buffered solution.
After lyophilization the vials are closed with a red screw cap.
b. Preparation of buffer-substrate pellets The following reagent solutions are prepared:
Solution 5: 200 ml 0.2 molar aqueous sodium-a-keto glutarate. The fresh solution is kept at 0 4C. until needed.
Solution 6: 800 ml of an aqueous solution having the composition of solution 4.
Solution 6 is cooled to 0 4C. and then thoroughly mixed with solution 5.
Buffer-substrate pellets of 0.1 ml of this mixed solution are prepared according to Example I. They are filled into small polyethylene vials as shown in FIG. 2, each vial containing one pellet. After lyophilization the vials are closed with blue screw caps.
c. Performance of the kinetic U.V.-assay To a vial prepared as described in this example under (a), 0.5 ml of distilled water and 0.2 ml of the serum to be assayed are added using Marburg pipettes. After shaking, the resulting solution is brought quantitatively into a 25C. cuvette of an Eppendorf spectrophotometer. Pre-incubation takes place for about 10 minutes. During this time the endogenous substrate in the sample is being converted. Optical density is read until constant. Then a blue'capped vial is opened and 0.1 ml distilled water is added with a Marburg pipette. The clear solution is then brought quantitatively into the euvette and thoroughly mixed.
Optical density readings are made then every 30 seconds, and the decrease is noted for at least 2 minutes. The values obtained are averaged, and the S.G.P.T. activity of the sample is calculated using the formula:
I.U. A O.D./min X 667 p. Mole X min" litre".
What is claimed is: l. A pregnancy test reagent adapted for detecting the presence of human chorionic gonadotropin in urine consisting essentially of astable frozen and freeze-dried pellet containing a predetermined immunologically effective amount for test purposes of human chorionic gonadotropin antiserum together, with an effective amount of a phosphate buffer.

Claims (1)

  1. 2. A pregnancy test reagent adapted for detecting the presence of human chorionic gonadotropin in urine consisting essentially of a stable frozen and freeze-dried pellet containing a predetermined immunologically effective amount for test purposes of human chorionic gonadotropin antiserum together with an effective amount of a phosphate buffer.
US186473A 1969-03-20 1971-10-04 Pelletized pregnancy test reagents Expired - Lifetime US3862302A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80880369A 1969-03-20 1969-03-20

Publications (1)

Publication Number Publication Date
US3862302A true US3862302A (en) 1975-01-21

Family

ID=25199790

Family Applications (2)

Application Number Title Priority Date Filing Date
US808803A Expired - Lifetime US3655838A (en) 1969-03-20 1969-03-20 Method of pelletizing analytical or immunological reagents
US186473A Expired - Lifetime US3862302A (en) 1969-03-20 1971-10-04 Pelletized pregnancy test reagents

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US808803A Expired - Lifetime US3655838A (en) 1969-03-20 1969-03-20 Method of pelletizing analytical or immunological reagents

Country Status (12)

Country Link
US (2) US3655838A (en)
JP (1) JPS5334518B1 (en)
BE (1) BE747699A (en)
CH (1) CH546570A (en)
DE (1) DE2013498A1 (en)
ES (1) ES377661A1 (en)
FI (1) FI52409C (en)
FR (1) FR2037234A1 (en)
GB (1) GB1304045A (en)
IL (1) IL34041A (en)
NL (1) NL7003963A (en)
SE (1) SE376087B (en)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995019A (en) * 1975-03-04 1976-11-30 Baxter Travenol Laboratories, Inc. Diagnostic reagent system
US4003988A (en) * 1976-06-01 1977-01-18 Warner-Lambert Company Direct agglutination test for pregnancy
US4184849A (en) * 1977-12-05 1980-01-22 Technicon Instruments Corporation Mixed agglutination
US4282002A (en) * 1979-09-06 1981-08-04 Akzona Incorporated Sensitized sheep stroma immunoassay for rheumatoid factor
US4295280A (en) * 1980-03-17 1981-10-20 American Home Products Corporation Method of obtaining a lyophilized product
US4308026A (en) * 1976-09-29 1981-12-29 Mochida Seiyaku Kabushiki Kaisha Agglutination inhibition immunoassay for hapten using two differently sensitized particles
US4320111A (en) * 1977-06-14 1982-03-16 American Home Products Corporation Immunologic compositions methods of preparation and use
US4351158A (en) * 1980-01-22 1982-09-28 American Home Products Corporation Method of producing multicomponent lyophilized product
US4447527A (en) * 1980-09-02 1984-05-08 Syva Company Single test formulations for enzyme immunoassays and method for preparation
US4587222A (en) * 1980-02-15 1986-05-06 Laboratories Polypharma Reagent comprising treated red blood cells and methods for detecting rheumatoid factor
US4712310A (en) * 1986-09-15 1987-12-15 E. I. Du Pont De Nemours And Company Co-spray technique
US4780285A (en) * 1985-08-19 1988-10-25 Akzo N.V. Device for the carrying out of an immunochemical determination
WO1989006976A1 (en) * 1988-02-01 1989-08-10 Quadrant Bioresources Limited Method of drying macromolecules
US4988627A (en) * 1987-12-18 1991-01-29 Eastman Kodak Company Test device with dried reagent drops on inclined wall
EP0641389A1 (en) 1991-08-19 1995-03-08 Abaxis, Inc. Reagent compositions for analytical testing
FR2756196A1 (en) * 1996-11-25 1998-05-29 Air Liquide Granule preparation process
US6165796A (en) * 1997-11-26 2000-12-26 Beckman Coulter, Inc. Pipettable ion detector and method
US6251684B1 (en) 1991-08-19 2001-06-26 Abaxis, Inc. Dried chemical compositions
US20080172902A1 (en) * 2006-06-20 2008-07-24 Octapharma Ag Lyophilisation targeting defined residual moisture by limited desorption energy levels
US20090107000A1 (en) * 2004-02-17 2009-04-30 Georg-Wilhelm Oetjen Method and Device for Freeze-Drying Products
US20090137029A1 (en) * 2007-06-21 2009-05-28 Gen-Probe Incorporated Multi-Chambered Receptacles
WO2009115608A2 (en) * 2008-03-20 2009-09-24 Iti Scotland Limited Uses of reagents in sample collection and cartridge systems
WO2010088496A1 (en) 2009-01-30 2010-08-05 Gen-Probe Incorporated Systems and methods for detecting a signal and applying thermal energy to a signal transmission element

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3955923A (en) * 1973-01-31 1976-05-11 Ortho Pharmaceutical Corporation Serologic reaction method
US4323478A (en) * 1977-01-18 1982-04-06 Baxter Travenol Laboratories, Inc. Novel particulate compositions
US4211015A (en) * 1978-01-18 1980-07-08 Baxter Travenol Laboratories, Inc. Method and apparatus for making novel particulate compositions
US4289748A (en) * 1979-05-31 1981-09-15 United States Of America Ultrasensitive enzymatic radioimmunoassay method
DE2925009A1 (en) * 1979-06-21 1981-01-08 Basf Ag PREPARATION FOR SUBSTANCES, METHOD FOR THE PRODUCTION AND USE THEREOF
CA1164340A (en) * 1980-09-02 1984-03-27 Alex A. Monte Single test compositions for immunoassays
JPS57149234U (en) * 1981-03-10 1982-09-18
JPS57183284U (en) * 1981-05-16 1982-11-20
DE3264450D1 (en) * 1981-12-11 1985-08-01 Wyeth John & Brother Ltd Process and apparatus for freezing a liquid medium
JPS6183569U (en) * 1984-11-08 1986-06-02
EP0266859A1 (en) * 1986-10-06 1988-05-11 Taiyo Sanso Co Ltd. Method and apparatus for producing microfine frozen particles
CH674410A5 (en) * 1987-05-25 1990-05-31 Rosenmund Ag
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
IL120202A (en) 1996-03-07 2001-03-19 Akzo Nobel Nv Container with freeze-dried vaccine components
US6354091B1 (en) * 2001-02-01 2002-03-12 Spectral Diagnostics, Inc. Apparatus and method for the production of frozen beads
US6780581B2 (en) 2001-09-12 2004-08-24 Btf Pty Ltd Products comprising quantum of bioparticles and method for production thereof
AUPR750501A0 (en) * 2001-09-05 2001-09-27 Gauci, Mark Products comprising quantum of bioparticles and method for production thereof
US6755886B2 (en) * 2002-04-18 2004-06-29 The Regents Of The University Of California Method for producing metallic microparticles
GB0522193D0 (en) 2005-10-31 2005-12-07 Axis Shield Asa Method
US20080075777A1 (en) * 2006-07-31 2008-03-27 Kennedy Michael T Apparatus and methods for preparing solid particles
FR2906688B1 (en) 2006-10-09 2012-04-20 Lavisse Isabelle Desjardins PROCESS FOR OBTAINING A PRODUCT SUBJECT TO GASIFICATION AND FREEZING
KR101695800B1 (en) 2008-03-05 2017-02-22 사노피 파스퇴르 Process for stabilizing an adjuvant containing vaccine composition
EP2143440A1 (en) 2008-07-09 2010-01-13 Sanofi Pasteur Stabilising agent and vaccine composition comprising one or several attenuated living flavivirus
US20130008191A1 (en) * 2011-07-07 2013-01-10 Suchak Naresh J Methods for freezing and thawing proteins
US10183968B2 (en) 2011-10-31 2019-01-22 Merck Sharp & Dohme Corp. Methods of preparing lyophilized spherical-shaped pellets of biological materials
JP6855469B2 (en) 2015-10-16 2021-04-07 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Steps for preparing a prescription for gastrointestinal targeted therapy
US11867460B2 (en) 2018-06-20 2024-01-09 Gen-Probe Incorporated Method and apparatus for freezing dispensed droplets of liquid
CN109619672B (en) * 2019-02-18 2021-09-28 重庆中烟工业有限责任公司 Capsule for cigarette, preparation method thereof and filter tip
JP6691256B1 (en) * 2019-07-25 2020-04-28 大阪ガスリキッド株式会社 Frozen body manufacturing equipment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236732A (en) * 1962-01-22 1966-02-22 Edward R Arquilla Pregnancy test method and immunological indicator therefor
US3344617A (en) * 1965-02-25 1967-10-03 Union Carbide Corp Apparatus for the preservation of biological substances
US3548051A (en) * 1966-03-24 1970-12-15 Organon Preparation of erythrocytes for immunochemical determination of human chorionic gonadotropin
US3579306A (en) * 1969-01-22 1971-05-18 Organon Diagnostic test device
US3654090A (en) * 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236732A (en) * 1962-01-22 1966-02-22 Edward R Arquilla Pregnancy test method and immunological indicator therefor
US3344617A (en) * 1965-02-25 1967-10-03 Union Carbide Corp Apparatus for the preservation of biological substances
US3548051A (en) * 1966-03-24 1970-12-15 Organon Preparation of erythrocytes for immunochemical determination of human chorionic gonadotropin
US3654090A (en) * 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US3654090B1 (en) * 1968-09-24 1982-07-20
US3579306A (en) * 1969-01-22 1971-05-18 Organon Diagnostic test device

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995019A (en) * 1975-03-04 1976-11-30 Baxter Travenol Laboratories, Inc. Diagnostic reagent system
US4003988A (en) * 1976-06-01 1977-01-18 Warner-Lambert Company Direct agglutination test for pregnancy
US4308026A (en) * 1976-09-29 1981-12-29 Mochida Seiyaku Kabushiki Kaisha Agglutination inhibition immunoassay for hapten using two differently sensitized particles
US4320111A (en) * 1977-06-14 1982-03-16 American Home Products Corporation Immunologic compositions methods of preparation and use
US4184849A (en) * 1977-12-05 1980-01-22 Technicon Instruments Corporation Mixed agglutination
US4282002A (en) * 1979-09-06 1981-08-04 Akzona Incorporated Sensitized sheep stroma immunoassay for rheumatoid factor
US4351158A (en) * 1980-01-22 1982-09-28 American Home Products Corporation Method of producing multicomponent lyophilized product
US4587222A (en) * 1980-02-15 1986-05-06 Laboratories Polypharma Reagent comprising treated red blood cells and methods for detecting rheumatoid factor
US4295280A (en) * 1980-03-17 1981-10-20 American Home Products Corporation Method of obtaining a lyophilized product
US4447527A (en) * 1980-09-02 1984-05-08 Syva Company Single test formulations for enzyme immunoassays and method for preparation
US4780285A (en) * 1985-08-19 1988-10-25 Akzo N.V. Device for the carrying out of an immunochemical determination
US4712310A (en) * 1986-09-15 1987-12-15 E. I. Du Pont De Nemours And Company Co-spray technique
US4988627A (en) * 1987-12-18 1991-01-29 Eastman Kodak Company Test device with dried reagent drops on inclined wall
WO1989006976A1 (en) * 1988-02-01 1989-08-10 Quadrant Bioresources Limited Method of drying macromolecules
EP0641389A1 (en) 1991-08-19 1995-03-08 Abaxis, Inc. Reagent compositions for analytical testing
US6251684B1 (en) 1991-08-19 2001-06-26 Abaxis, Inc. Dried chemical compositions
EP0641389B2 (en) 1991-08-19 2007-08-22 Abaxis, Inc. Reagent compositions for analytical testing
FR2756196A1 (en) * 1996-11-25 1998-05-29 Air Liquide Granule preparation process
US6165796A (en) * 1997-11-26 2000-12-26 Beckman Coulter, Inc. Pipettable ion detector and method
US20090107000A1 (en) * 2004-02-17 2009-04-30 Georg-Wilhelm Oetjen Method and Device for Freeze-Drying Products
US20080172902A1 (en) * 2006-06-20 2008-07-24 Octapharma Ag Lyophilisation targeting defined residual moisture by limited desorption energy levels
US8769841B2 (en) 2006-06-20 2014-07-08 Octapharma Ag Lyophilisation targeting defined residual moisture by limited desorption energy levels
US8480976B2 (en) 2007-06-21 2013-07-09 Gen-Probe Incorporated Instruments and methods for mixing the contents of a detection chamber
EP2465609A1 (en) 2007-06-21 2012-06-20 Gen-Probe Incorporated Instruments and method for mixing the contents of a detection chamber
US11235295B2 (en) 2007-06-21 2022-02-01 Gen-Probe Incorporated System and method of using multi-chambered receptacles
US11235294B2 (en) 2007-06-21 2022-02-01 Gen-Probe Incorporated System and method of using multi-chambered receptacles
EP2191897A1 (en) 2007-06-21 2010-06-02 Gen-Probe Incorporated Instrument and receptacles for performing processes
US7767447B2 (en) 2007-06-21 2010-08-03 Gen-Probe Incorporated Instruments and methods for exposing a receptacle to multiple thermal zones
US10744469B2 (en) 2007-06-21 2020-08-18 Gen-Probe Incorporated Multi-chambered receptacles
US7780336B2 (en) 2007-06-21 2010-08-24 Gen-Probe Incorporated Instruments and methods for mixing the contents of a detection chamber
US10688458B2 (en) 2007-06-21 2020-06-23 Gen-Probe Incorporated System and method of using multi-chambered receptacles
US20110189661A1 (en) * 2007-06-21 2011-08-04 Gen-Probe Incorporated Gravity-assisted mixing methods
US8048375B2 (en) 2007-06-21 2011-11-01 Gen-Probe Incorporated Gravity-assisted mixing methods
US8052929B2 (en) 2007-06-21 2011-11-08 Gen-Probe Incorporated Gravity-assisted mixing methods
EP2425894A1 (en) 2007-06-21 2012-03-07 Gen-Probe Incorporated Instruments and method for exposing a receptacle to multiple thermal zones
US20090142745A1 (en) * 2007-06-21 2009-06-04 Gen-Probe Incorporated Instruments and methods for exposing a receptacle to multiple thermal zones
US20090136913A1 (en) * 2007-06-21 2009-05-28 Gen-Probe Incorporated Gravity-Assisted Mixing Methods
US8491178B2 (en) 2007-06-21 2013-07-23 Gen-Probe Incorporated Instruments and methods for mixing the contents of a detection chamber
US9744506B2 (en) 2007-06-21 2017-08-29 Gen-Probe Incorporated Instruments for mixing the contents of a detection chamber
US8735055B2 (en) 2007-06-21 2014-05-27 Gen-Probe Incorporated Methods of concentrating an analyte
US8765367B2 (en) 2007-06-21 2014-07-01 Gen-Probe Incorporated Methods and instruments for processing a sample in a multi-chambered receptacle
US20090137029A1 (en) * 2007-06-21 2009-05-28 Gen-Probe Incorporated Multi-Chambered Receptacles
US8784745B2 (en) 2007-06-21 2014-07-22 Gen-Probe Incorporated Methods for manipulating liquid substances in multi-chambered receptacles
US8828654B2 (en) 2007-06-21 2014-09-09 Gen-Probe Incorporated Methods for manipulating liquid substances in multi-chambered receptacles
US8669110B2 (en) * 2008-03-20 2014-03-11 Prabhjyot Dehal Uses of reagents in sample collection and cartridge systems
US20110059547A1 (en) * 2008-03-20 2011-03-10 Iti Scotland Limited Uses of reagents in sample collection and cartridge systems
WO2009115608A3 (en) * 2008-03-20 2009-12-03 Iti Scotland Limited Uses of reagents in sample collection and cartridge systems
WO2009115608A2 (en) * 2008-03-20 2009-09-24 Iti Scotland Limited Uses of reagents in sample collection and cartridge systems
WO2010088496A1 (en) 2009-01-30 2010-08-05 Gen-Probe Incorporated Systems and methods for detecting a signal and applying thermal energy to a signal transmission element

Also Published As

Publication number Publication date
JPS5334518B1 (en) 1978-09-21
FI52409B (en) 1977-05-02
BE747699A (en) 1970-09-21
CH546570A (en) 1974-03-15
ES377661A1 (en) 1973-02-01
FR2037234A1 (en) 1970-12-31
GB1304045A (en) 1973-01-24
DE2013498A1 (en) 1970-09-24
SE376087B (en) 1975-05-05
US3655838A (en) 1972-04-11
IL34041A0 (en) 1970-05-21
NL7003963A (en) 1970-09-22
FI52409C (en) 1977-08-10
IL34041A (en) 1973-05-31

Similar Documents

Publication Publication Date Title
US3862302A (en) Pelletized pregnancy test reagents
US4731330A (en) Whole blood control sample
JP3257795B2 (en) Unit-of-use reagent composition for specific binding assays
US4244694A (en) Reactor/separator device for use in automated solid phase immunoassay
US5009998A (en) Method for performing heterogeneous immunoassay
JPS6243138B2 (en)
US7498028B2 (en) Preparation of spheres for diagnostic tests
US4348207A (en) Method and means for determination of pregnancy
US4360358A (en) Immunoassay with solid phase having coating containing blood platelet substitute
US4351158A (en) Method of producing multicomponent lyophilized product
US3562384A (en) Immunological indicator and test system
JP3290660B2 (en) Unit-of-use reagent composition for specific binding assay
US4780285A (en) Device for the carrying out of an immunochemical determination
US4052504A (en) Assay for thyroxine binding globulin
US5093271A (en) Method for the quantitative determination of antigens and antibodies by ratio of absorbances at different wavelengths
US4295280A (en) Method of obtaining a lyophilized product
EP0267944A1 (en) Binding assays involving formation and detection of light-scattering crystals
US4548908A (en) Competitive immunofluorescence assay and test kit
US4506019A (en) Activated polymer container means and assay method employing the same
EP0607209B1 (en) Unit-of-use reagent compositions for specific binding assays
Lash et al. Radioimmunoassay of angiotensin I, for estimation of plasma renin activity
EP0108136B1 (en) Competitive immunofluorescence assay and test kit
JPS5873866A (en) Immunological method for detection
JP2004170127A (en) Blood corpuscle reagent for antibody test
JPS6031058A (en) Pregnancy diagnostic reagent